The Access Criteria for the oral antiviral COVID-19 treatments, nirmatrelvir with ritonavir (Paxlovid) and molnupiravir (Lagevrio) has been announced.
These Access Criteria have been developed with the advice of clinical expert advisors. Supply of the oral treatments will be arriving throughout 2022 and the criteria have been designed to help support prescribers to target available supply to those most in need and most likely to benefit.
Approvals are valid for patients where the prescribing clinician confirms the patient meets the following criteria and has endorsed the prescription accordingly.
For more information please click on this link: https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-03-31-decision-on-access-criteria-for-two-oral-covid-19-treatments